TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28758128

Group type: COMPARATOR
Intervention: Face-to-face training during paediatric practice
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Training videos supervised by sanitary personnel
Number of subjects: 50
Study: 26096070

Group type: EXPERIMENTAL
Intervention: MB‐TKA inserts
Number of subjects: 146

Group type: COMPARATOR
Intervention: FB‐TKA inserts
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Goniometry, temporal gait parameters and QoL
Number of subjects: 146
Study: 24832767

Group type: EXPERIMENTAL
Intervention: Cavotricuspid isthmus ablation with concomitant pulmonary vein isolation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cavotricuspid isthmus ablation only
Number of subjects: 50
Study: 20859682

Group type: EXPERIMENTAL
Intervention: High-concentrate (HC) group received a diet that supplied 1.5 times their maintenance requirements.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Medium-concentrate (MC) group received a diet that supplied 1.2 times their maintenance requirements.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control-concentrate (CC) group received 1.0 times their maintenance requirements.
Number of subjects: 24
Study: 19826022

Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 881

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 881
Study: 17471084

Group type: EXPERIMENTAL
Intervention: Active management group (Back Book)
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Postural hygiene group (Back Guide)
Number of subjects: 661

Group type: COMPARATOR
Intervention: Control group (pamphlet on cardiovascular health)
Number of subjects: 661
Study: 15096395

Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/d
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/d
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Topiramate 50 mg/d
Number of subjects: 487

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study: 11552899

Group type: EXPERIMENTAL
Intervention: NSAIDs (n=6)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-NSAIDs (n=9)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Surveillance colonoscopy (n=23)
Number of subjects: 38
Study: 9169285

Group type: EXPERIMENTAL
Intervention: Lamotrigine with Felbamate (FBM)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Lamotrigine monotherapy
Number of subjects: 11
Study: 8109939

Group type: EXPERIMENTAL
Intervention: M500 tablet formulation (500 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: M250 tablet formulation (500 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical-trial formulation (500 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Syrup formulation (500 mg) with food
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Syrup formulation (500 mg) fasting
Number of subjects: 0
Study: 3090987

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination chemotherapy (5‐fluorouracil, doxorubicin and cyclophosphamide)
Number of subjects: 0
Study: 31910218

Group type: EXPERIMENTAL
Intervention: High definition tDCS (HD-tDCS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Anodal tDCS (a-tDCS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24
Study: 30150014

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg once daily administered orally)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Vinorelbine and cisplatin chemotherapy (four cycles of vinorelbine [25 mg/m2 intravenously on days 1 and 8 of each 21-day cycle] plus cisplatin [75 mg/m2 intravenously on day 1 of each 21-day cycle])
Number of subjects: 102
Study: 26920705

Group type: EXPERIMENTAL
Intervention: Post-tetanic count (PTC) with 50-Hz tetanus followed by a three-second pause and 15 1-Hz stimuli
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no PTC)
Number of subjects: 22
Study: 24679550

Group type: EXPERIMENTAL
Intervention: Treadmill-exercise program for 12 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Customary lifestyle (Control)
Number of subjects: 46
Study: 22369217

Group type: EXPERIMENTAL
Intervention: Expectancy Challenge Alcohol Literacy Curriculum (ECALC)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control presentation
Number of subjects: 250
Study: 20170878

Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.5 mg/kg IV, 0.3 mg/kg SC)
Number of subjects: 2452

Group type: COMPARATOR
Intervention: Unfractionated Heparin (40 U/kg IV, 3,000 U maximum)
Number of subjects: 2452
Study: 18405409

Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nitrous oxide anaesthesia
Number of subjects: 64
Study: 15889218

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin‐clavulanic acid 1.313 g 2 hours before operation (n = 208)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Parenteral amoxicillin‐clavulanic acid 1.2 g intravenously 30 minutes before surgery (n = 200)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 480
Study: 14529684

Group type: EXPERIMENTAL
Intervention: Music group (slow-rhythm music played during colposcopy)
Number of subjects: 220

Group type: COMPARATOR
Intervention: No-music group (no music played during colposcopy)
Number of subjects: 220
Study: 10506395

Group type: EXPERIMENTAL
Intervention: Intensified therapy (pravastatin 20‐40 mg with addition of colestyramine and/or nicotinic acid)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Intensified therapy
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional therapy (usual care antilipidemic therapy)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 126
Study: 8878253

Group type: EXPERIMENTAL
Intervention: Dexamethasone, 3 mg every eight hours for 48 hr
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8297645

Group type: EXPERIMENTAL
Intervention: Mitotic count
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Presence or absence of necrosis
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Size of the tumour
Number of subjects: 282
Study: 3525337

Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg at night
Number of subjects: 428

Group type: COMPARATOR
Intervention: ranitidine 150 mg twice daily
Number of subjects: 428
Study: 30676234

Group type: EXPERIMENTAL
Intervention: Active treatment (blue/red light therapy patch)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham treatment (placebo)
Number of subjects: 34
Study: 29338133

Group type: EXPERIMENTAL
Intervention: Pimasertib
Number of subjects: 8
Study: 27211525

Group type: EXPERIMENTAL
Intervention: Mentored delivery of obesity prevention toolkit
Number of subjects: 150

Group type: COMPARATOR
Intervention: Mailed delivery of obesity prevention toolkit
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both groups (mentored and mailed)
Number of subjects: 150
Study: 23688103

Group type: EXPERIMENTAL
Intervention: Flapless procedure
Number of subjects: 64

Group type: COMPARATOR
Intervention: Full-thickness mucoperiosteal flap (Control)
Number of subjects: 64
Study: 22466910

Group type: EXPERIMENTAL
Intervention: Everolimus with mycophenolate sodium (720 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Everolimus with low-exposure cyclosporine (3-8 ng/mL)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CNI-free group
Number of subjects: 30
Study: 18031878

Group type: EXPERIMENTAL
Intervention: Warm packs applied to the perineum (n=360)
Number of subjects: 717

Group type: COMPARATOR
Intervention: Standard care (n=357)
Number of subjects: 717
Study: 17329688

Group type: EXPERIMENTAL
Intervention: Decline in total cerebral blood flow
Number of subjects: 390
Study: 15223743

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg)
Number of subjects: 0
Study: 11205935

Group type: EXPERIMENTAL
Intervention: Dorsiflexion strength in the more affected limb of PAOD patients (55 +/- 4 Newton-meters)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Dorsiflexor strength in PAOD group (73 +/- 6 Newton-meters)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Time to perform five sequential sit-to-stand transfers in PAOD group (13.0 +/- 0.5 s)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Correlation of dorsiflexor strength with chair stand time in PAOD patients
Number of subjects: 46
Study: 9204220

Group type: EXPERIMENTAL
Intervention: Daily self monitoring of blood pressure
Number of subjects: 0

Group type: COMPARATOR
Intervention: No daily self monitoring of blood pressure
Number of subjects: 0
Study: 7957457

Group type: EXPERIMENTAL
Intervention: Membrane oxygenator (D 701 Masterflo 34)
Number of subjects: 30
Study: 3296732

Group type: EXPERIMENTAL
Intervention: MTX, 250 mg/m2 followed 1 h later by 5-FU, 600 mg/m2
Number of subjects: 55

Group type: COMPARATOR
Intervention: 5-FU followed 1 h later by MTX in the same doses
Number of subjects: 55
Study: 31924247

Group type: EXPERIMENTAL
Intervention: Teaching Recovery Techniques (TRT) programme
Number of subjects: 218

Group type: COMPARATOR
Intervention: Services as usual (waitlist-control)
Number of subjects: 218
Study: 29324494

Group type: EXPERIMENTAL
Intervention: Glucose-Insulin-Potassium (GIK) - 20 IU of insulin, 10 mEq of potassium chloride in 50 mL of glucose 40%, administered over 60 minutes on anesthetic induction.
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Glucose-Insulin-Potassium (GIK)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Saline infusion (placebo)
Number of subjects: 224
Study: 26585988

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months (Q6M)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 3 months (Q3M)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 2 months (Q2M)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study: 25581656

Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/d
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Topiramate treatment
Number of subjects: 138
Study: 23732968

Group type: EXPERIMENTAL
Intervention: Maintenance cognitive-behavioral therapy (CBT)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Manualized psychoeducation
Number of subjects: 180
Study: 20237485

Group type: EXPERIMENTAL
Intervention: Fisher and Paykel (FP) high-flow nasal cannula
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vapotherm (VT) high-flow nasal cannula
Number of subjects: 40
Study: 19105803

Group type: EXPERIMENTAL
Intervention: Follow-up and final examination in the hospital's emergency unit (Group A - ER)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Follow-up by general practitioner, final examination at hospital's emergency unit (Group B - GP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Self-acquired stabilizing ortheses (e.g., Aircast, Malleoloc)
Number of subjects: 100
Study: 16880771

Group type: EXPERIMENTAL
Intervention: Pergolide (0.1 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12717109

Group type: EXPERIMENTAL
Intervention: Flecainide acetate immediate-release (IR) 100 mg BID
Number of subjects: 48

Group type: COMPARATOR
Intervention: Flecainide acetate controlled-release (CR) 200 mg OD
Number of subjects: 48

Group type: COMPARATOR
Intervention: Comparison of IR and CR formulations
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: IR formulation
Number of subjects: 48

Group type: COMPARATOR
Intervention: CR formulation
Number of subjects: 48
Study: 10700443

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 368
Study: 8864020

Group type: EXPERIMENTAL
Intervention: Catheter flush with buffer solution through the sideport
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Washing the pumping unit with an alkaline solution after diverting pump flow at the sideport
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Procedures for managing decreased insulin flow
Number of subjects: 0
Study: 1832382

Group type: EXPERIMENTAL
Intervention: Isradipine (IS) 2.5‐7.5 mg three times daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nifedipine (NF) 10‐30 mg three times daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Isradipine (IS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nifedipine (NF)
Number of subjects: 18
Study: 6344266

Group type: EXPERIMENTAL
Intervention: CMF + immunotherapy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: CMF + vincristine + prednisone
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: CMF + prednisone
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: CMF + prednisone + tamoxifen
Number of subjects: 105

Group type: COMPARATOR
Intervention: tamoxifen
Number of subjects: 105
Study: 31665026

Group type: EXPERIMENTAL
Intervention: Adaptive Servo-Ventilation (ASV) therapy
Number of subjects: 177
Study: 29914782

Group type: EXPERIMENTAL
Intervention: Surgical TAP block (n=20)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional TAP block (n=21)
Number of subjects: 41
Study: 27226182

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 78

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 78
Study: 24977249

Group type: EXPERIMENTAL
Intervention: Definitive abutment (DA)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Provisional abutment (PA)
Number of subjects: 28
Study: 22325903

Group type: EXPERIMENTAL
Intervention: Atacicept (150 mg, subcutaneously, twice weekly for 4 weeks, then weekly) with MMF and tapered CS
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo with MMF and tapered CS
Number of subjects: 6
Study: 20561758

Group type: COMPARATOR
Intervention: Naltrexone 100mg
Number of subjects: 385

Group type: COMPARATOR
Intervention: Naltrexone (various doses)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Naltrexone treatment condition (100mg vs. placebo)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Gender
Number of subjects: 385

Group type: COMPARATOR
Intervention: IVR ratings of negative affect
Number of subjects: 385
Study: 17418730

Group type: EXPERIMENTAL
Intervention: Hypothermic CPB (32 degrees C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normothermic CPB (36 degrees C)
Number of subjects: 30
Study: 15777306

Group type: EXPERIMENTAL
Intervention: 10 mg hyperbaric bupivacaine at interspace L3‐4
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 10 mg bupivacaine through spinal catheter with EMG-guidance (Group CSA)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Single bolus of bupivacaine (15‐20 mg) at L3‐4 (Group Bolus)
Number of subjects: 29
Study: 12572376

Group type: EXPERIMENTAL
Intervention: Shutianing Granule (STNG) 9 g, three times a day for 28 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Composite Yangjiao capsule, 5 capsules each time, three times a day for 28 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Flunarizine hydrochloride capsule, 5 mg, once a day for 28 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All treated groups (including STNG, control A, and control B)
Number of subjects: 90
Study: 10219458

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8574332

Group type: EXPERIMENTAL
Intervention: enprostil (35 micrograms twice daily)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: misoprostol (200 micrograms four times daily)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: enprostil
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: misoprostol
Number of subjects: 214
Study: 2077745

Group type: EXPERIMENTAL
Intervention: Sodium oxybutyrate electrophoresis with sinusoidal modulated current plus sodium chloride baths
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus balneotherapy
Number of subjects: 0
Study: 381599

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Low-dose dexamethasone (16 mg/day)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (96 mg/day)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Dexamethasone (both doses)
Number of subjects: 76
Study: 30234733

Group type: EXPERIMENTAL
Intervention: FES-cycling
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard rehabilitation program (control group)
Number of subjects: 21
Study: 28160721

Group type: EXPERIMENTAL
Intervention: Attention-based psychological exercise
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Acceptance-based psychological exercise
Number of subjects: 77

Group type: COMPARATOR
Intervention: Progressive muscle relaxation control
Number of subjects: 77
Study: 26428286

Group type: EXPERIMENTAL
Intervention: Customized configuration for medication alert override reasons
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-customized configuration for medication alert override reasons
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Customized configuration for free-text responses
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-customized configuration for free-text responses
Number of subjects: 22
Study: 23298374

Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg/day for 1 week
Number of subjects: 10
Study: 21572305

Group type: EXPERIMENTAL
Intervention: Recent maternal HIV infection identified using the multiassay algorithm (MAA)
Number of subjects: 2561

Group type: COMPARATOR
Intervention: Not recently infected women
Number of subjects: 2561

Group type: EXPERIMENTAL
Intervention: Recent maternal HIV infection
Number of subjects: 2561

Group type: EXPERIMENTAL
Intervention: Log(10) HIV viral load at delivery
Number of subjects: 2561

Group type: EXPERIMENTAL
Intervention: Younger age (per 10 year increase)
Number of subjects: 2561
Study: 19620495

Group type: EXPERIMENTAL
Intervention: Lapatinib with paclitaxel
Number of subjects: 493

Group type: COMPARATOR
Intervention: Paclitaxel with placebo
Number of subjects: 493
Study: 16836164

Group type: EXPERIMENTAL
Intervention: 0.3 mg/mL rhPDGF‐BB + beta‐TCP
Number of subjects: 0

Group type: COMPARATOR
Intervention: beta‐TCP + buffer (active control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rhPDGF‐BB treatment groups
Number of subjects: 0
Study: 12776476

Group type: EXPERIMENTAL
Intervention: 10% dextrose injection
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 25% dextrose injection
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10% or 25% dextrose injection based on patient preference
Number of subjects: 18
Study: 10877732

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine, 0.5%, 15 mg (3 ml) injected intrathecally
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine, 0.5%, 15 mg (3 ml) injected intrathecally with torso elevated 30 degrees
Number of subjects: 40
Study: 9165550

Group type: EXPERIMENTAL
Intervention: Morning dose of tacrolimus
Number of subjects: 12

Group type: COMPARATOR
Intervention: Evening dose of tacrolimus
Number of subjects: 12
Study: 1375485

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus G‐CSF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peripheral blood mononuclear cells harvested after chemotherapy plus G‐CSF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pretreatment blood
Number of subjects: 0
Study: 3910524

Group type: EXPERIMENTAL
Intervention: Vancomycin (500 mg six hourly for seven days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (500 mg six hourly for seven days)
Number of subjects: 40
Study: 30720338

Group type: EXPERIMENTAL
Intervention: Day-and-night hybrid closed-loop system
Number of subjects: 24
Study: 29703793

Group type: COMPARATOR
Intervention: MET 1000 mg BID
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: COMBI (MET 1000 mg BID + liraglutide 1.2 mg QD s.c.)
Number of subjects: 28
Study: 27568804

Group type: EXPERIMENTAL
Intervention: Early adenotonsillectomy (eAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Watchful waiting with supportive care (WWSC)
Number of subjects: 0
Study: 25311606

Group type: EXPERIMENTAL
Intervention: Neighborhood food and service retail scale
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Neighborhood physical disorder scale
Number of subjects: 174
Study: 23040114

Group type: EXPERIMENTAL
Intervention: Lower hemoglobin levels (≤ 11 g/dL)
Number of subjects: 1763

Group type: EXPERIMENTAL
Intervention: Hemoglobin levels >11-12 g/dL
Number of subjects: 1763

Group type: EXPERIMENTAL
Intervention: Hemoglobin levels >12-13 g/dL
Number of subjects: 1763

Group type: EXPERIMENTAL
Intervention: Hemoglobin levels >13-14 g/dL
Number of subjects: 1763

Group type: EXPERIMENTAL
Intervention: Hemoglobin levels >14-15 g/dL
Number of subjects: 1763

Group type: EXPERIMENTAL
Intervention: Hemoglobin levels >15 g/dL
Number of subjects: 1763
Study: 19261825

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 890

Group type: COMPARATOR
Intervention: Control
Number of subjects: 890
Study: 17583621

Group type: EXPERIMENTAL
Intervention: Iron-fortified toddler formula (500 mL/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Unmodified cow's milk (500 mL/day)
Number of subjects: 33
Study: 15241911

Group type: EXPERIMENTAL
Intervention: Ozone application for 10 seconds
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ozone application for 20 seconds
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ozone application (10 or 20 seconds)
Number of subjects: 26
Study: 12575622

Group type: EXPERIMENTAL
Intervention: Palivizumab (SYNAGIS) - 5 monthly injections
Number of subjects: 1502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1502
Study: 9647273

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate powder at a dose of 16 mg/day administered by a metered dose inhaler (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate aqueous solution at a dose of 80 mg/day administered by a nebulizer (Group N)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate aqueous solution (80 mg/day) combined with salbutamol (3 mg/day) administered by a nebulizer (Group C)
Number of subjects: 0
Study: 7912950

Group type: EXPERIMENTAL
Intervention: Neuroleptanaesthesia (fentanyl and droperidol)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 1 MAC of halothane with 66% nitrous oxide in oxygen
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 1 MAC of isoflurane with 66% nitrous oxide in oxygen
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 1 MAC of enflurane with 66% nitrous oxide in oxygen
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 1 MAC of sevoflurane with 66% nitrous oxide in oxygen
Number of subjects: 75